A Distinct Microbiome Signature in Posttreatment Lyme Disease Patients

Autor: Mark J. Soloski, Anthony D'Onofrio, Philip Strandwitz, Alison W. Rebman, Antonio Gonzalez, Mariaelena Caboni, Madeleine Morrissette, John N. Aucott, Rob Knight, Norman Pitt, Kim Lewis
Přispěvatelé: Gilmore, Michael S
Jazyk: angličtina
Rok vydání: 2020
Předmět:
0301 basic medicine
Male
Antibiotics
Disease
law.invention
Cohort Studies
Feces
0302 clinical medicine
Lyme disease
law
diagnostics
2.1 Biological and endogenous factors
Aetiology
screening and diagnosis
Post-Lyme Disease Syndrome
Incidence (epidemiology)
Microbiota
Middle Aged
Intensive care unit
QR1-502
Anti-Bacterial Agents
Detection
Infectious Diseases
Cohort
Female
tick-borne pathogens
Research Article
Adult
medicine.medical_specialty
medicine.drug_class
microbial communities
Microbiology
Host-Microbe Biology
03 medical and health sciences
Clinical Research
Virology
Internal medicine
medicine
Genetics
Humans
Microbiome
Bacteria
business.industry
Prevention
medicine.disease
Editor's Pick
4.1 Discovery and preclinical testing of markers and technologies
030104 developmental biology
Emerging Infectious Diseases
Etiology
Dysbiosis
microflora
business
Transcriptome
030217 neurology & neurosurgery
Zdroj: mBio, Vol 11, Iss 5 (2020)
mBio
mBio, vol 11, iss 5
ISSN: 2150-7511
DOI: 10.1128/mBio.02310-20
Popis: Most patients with acute Lyme disease are cured with antibiotic intervention, but 10 to 20% endure debilitating symptoms such as fatigue, neurological complications, and myalgias after treatment, a condition known as posttreatment Lyme disease syndrome (PTLDS). The etiology of PTLDS is not understood, and objective diagnostic tools are lacking. PTLDS symptoms overlap several diseases in which patients exhibit alterations in their microbiome. We found that patients with PTLDS have a distinct microbiome signature, allowing for an accurate classification of over 80% of analyzed cases. The signature is characterized by an increase in Blautia, a decrease in Bacteroides, and other changes. Importantly, this signature supports the validity of PTLDS and is the first potential biological diagnostic tool for the disease.
Lyme disease is the most common vector-borne disease in the United States, with an estimated incidence of 300,000 infections annually. Antibiotic intervention cures Lyme disease in the majority of cases; however, 10 to 20% of patients develop posttreatment Lyme disease syndrome (PTLDS), a debilitating condition characterized by chronic fatigue, pain, and cognitive difficulties. The underlying mechanism responsible for PTLDS symptoms, as well as a reliable diagnostic tool, has remained elusive. We reasoned that the gut microbiome may play an important role in PTLDS given that the symptoms overlap considerably with conditions in which a dysbiotic microbiome has been observed, including mood, cognition, and autoimmune disorders. Analysis of sequencing data from a rigorously curated cohort of patients with PTLDS revealed a gut microbiome signature distinct from that of healthy control subjects, as well as from that of intensive care unit (ICU) patients. Notably, microbiome sequencing data alone were indicative of PTLDS, which presents a potential, novel diagnostic tool for PTLDS.
Databáze: OpenAIRE
Externí odkaz: